PosterSessionOnline

BRITISH SOCIETY FOR HAEMATOLOGY

62nd Annual Scientific Meeting of the British Society for Haematology

3-5 April 2022 Manchester

N. Poster

Poster title

Applicant name

Status


PO-001	Oral azacitidine in patients with acute myeloid leukemia in first remission after intensive chemotherapy: long-term overall survival results from the phase 3 QUAZAR AML-001 trial	Dale Owens	Received

EP-001	Next generation sequencing in myeloid neoplasms: the South East of Scotland Experience	Christopher Mullen	Received

EP-002	Are Individuals of a Lower Socio-Economic Class Not Able to Receive Treatment for Acute Myeloid Leukemia due to Cost? A Prospective Analysis of 200 Patients in India.	Sasmith Menakuru	Received

EP-003	The UK Real-world Experience of CPX-351 for the Treatment of Therapy-related Acute Myeloid Leukaemia and Acute Myeloid Leukaemia with Myelodysplasia-related Changes: CREST Retrospective Clinical Trial Design	Priyanka Mehta	Received

PO-004	Performances of Targeted RNA Sequencing for the Analysis of Fusion, Mutation, Exon Skipping and Expression in Hematological Tumors	Jing Li	Received

EP-004	Leukocytapheresis for hyperleukocytosis in acute myeloid leukaemia a survey of current practice	Julia Wolf	Received

PO-005	Beyond the In-Practice CBC: The Research CBC Parameters-Driven Machine Learning Predictive Modeling for Early Differentiation among Leukemias	Rana Zeeshan Haider	Received

EP-005	Blinatumomab and inotuzumab ozogamicin for acute lymphoblastic leukaemia: data from the South East Scotland Cancer Network	Christopher Mullen	Received

PO-006	One size fits all: a fixed (not weight-adjusted) dose of prophylactic liposomal amphotericin B is not associated with a higher rate of breakthrough invasive fungal infections in patients with higher weight	Sion Williams	Received

EP-006	Fever-to-needle time in the neutropenic cohort: are we meeting the gold-standard?	Kritika Kalia	Received

EP-007	Single Center, Real-world Retrospective Analysis of the Use of Azacitadine and Venetoclax as First Line Treatment In Patients with Acute Myeloid Leukaemia During the COVID-19 Pandemic	Sarah Ahmed Bassiony	Received

PO-007	Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Therapy-related Myeloid Neoplasms, Antecedent Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	Kathryn Moulton	Received

PO-008	CPX-351 Treatment for Acute Myeloid Leukaemia in England: Real-world Outcomes in Adults Aged 60 Years	Alex Legg	Received

EP-008	A simple intervention improved compliance with the COVID-19 swabbing policy for patients receiving chemotherapy in the Royal Bolton Hospital haematology department	Lowri Edwards	Received

EP-010	Analysis of Haematology Consult Cases to Design a Consult Request Pro Forma in a Tertiary University Teaching Hospital	David Egong	Received

PO-011	Purified phospholipase A2 from Pseudechis australis snake venom a novel anticancer agent for the treatment of precursor-B acute lymphoblastic leukaemia.	James Boncan	Received

PO-012	Management of non-severe aplastic anemia: laboratory workup and treatment patterns.	Giulio Cassanello	Received

EP-012	Review of bone marrow aspiration and trephine biopsies; a single university hospital report	Zahraa Al-Dulaimi	Received

EP-013	Review of local practice and experience: a survey regarding bone marrow biopsies in a UK tertiary centre	Kiri Dixon	Received

PO-013	Reporting Language in Haematological Malignancies	Sophie Ralston	Received

PO-014	Audit outcomes of the Referral Pathway for Haematology Patients to the Intensive Care Facility at the University Hospital of Wales During the COVID Pandemic	Medhavi Ratnayake	Received

EP-014	Haematology SpR Patient Safety Lead: A valuable contribution to Clinical Governance	Michelle Melly	Received

EP-015	Thrombocytopenia in COVID-19 patients on ECMO	Can Jones	Received

PO-015	Choose your own story: combining interactive voting technology with high-fidelity patient simulation for undergraduate transfusion teaching	Sophie Holmes	Received

EP-016	Dasatinib Related Pleural Effusions: Real-World Experience in a District General Hospital	Wing Yee Chris Sin	Received

PO-016	Under or delayed transfusion: Risk factors leading to patient deaths.	Shruthi Narayan	Received

PO-017	Reducing Unnecessary Blood Tests on a Haematology Ward at Salisbury NHS Foundation Trust	Lee Grimes	Received

EP-017	Adherence to national guidelines for patients with very low B12 levels 15Ong/l	Wayne Thomas	Received

PO-018	A multidisciplinary approach to improvement of a bone marrow biopsy service: advice from both service users and service providers	Kiri Dixon	Received

EP-018	PERFORMANCE OF SOME HAEMATOLOGICAL MARKERS OF SYSTEMIC INFLAMMATORY RESPONSE IN PREECLAMPSIA	Theresa Nwagha	Received

PO-019	Home transfusions balancing safety with individualised care	Shruthi Narayan	Received

EP-019	Prevalence and clinicopathological features of driver mutations in BCR-ABL1 negative classical myeloproliferative neoplasm- A single centre study from North India	Khaliqur Rahman	Received

EP-020	IMMUNE THROMBOCYTOPENIA: BE ALWAYS AWARE	Paula Melero Valentín	Received

PO-020	Endocrine Complications in Patients with Thalassemia: A Single Centre Experience	Maab Ibrahim	Received

PO-021	The Haematology Taster Day Inspiring the next generation of haematologists	Julia Wolf	Received

EP-021	Platelets Indices as Diagnostic Markers for Immune Thrombocytopenia and Surrogate Predictors for Prednisolones Response, Khartoum - Sudan	Rabea Saeed	Received

PO-022	Strangers in a foreign land: Foundation year 1 doctors introduction and experiences in Haematology-Oncology	Alessandra Lepori	Received

EP-022	Effect of Iron Deficiency Anemia on HbA1c levels in a cohort of patients with Type 2 diabetes mellitus(T2DM) in Sri Lanka.	Chitranga Kariyawasan	Received

PO-023	Developing the role of the Haematology ward in undergraduate medical education with the creation of a novel clinical placement	Richard Hinton	Received

EP-023	Usefulness of Ferritin and sTfR/(log)ferritin (sTfR-F) index in identifying iron deficiency anaemia among blood donors	Theresa Nwagha	Received

EP-024	Reducing Platelet Wastage in a Regional Australian Haematology Centre: Impact of Phone Calls to Clinical Staff for Expiring Platelet Stock	Emily Powley	Received

PO-024	Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies	Cory Pfeiffenberger	Received

EP-025	Increasing incidence of Folate and Vitamin B12 deficiency in pregnant population and Risk Stratification of at risk women with early diagnosis and management	Rakhee Saxena	Received

PO-025	Treatment free responses and long term outcomes in ITP patients with an optimal response to thrombopoietin receptor agonists	Asad Charania	Received

EP-026	Evaluation of the hematological changes in the full blood count of regular apheresis platelet donors at National Blood Centre Narahenpita in Sri Lanka.	Gauri Jayasinghe	Received

PO-026	Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib	Gemma Shay-Lowell	Received

PO-027	Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis update of clinical and translational data from the ongoing MANIFEST trial	Hannah Greetham	Received

EP-027	Assessment of the Relationship between ferritin levels and hematological ratios in Thalassemia Major	Dorra Rhim	Received

PO-028	EMT transcription factor Zeb1 regulates T-cell differentiation from haematopoietic stem cells during ontogenesis	Hamed Alzahrani	Received

EP-028	Adapting heparin monitoring in response to COVID-19	Emily Patrick	Received

EP-029	Impact Of National Hemovigilance Reporting System: A Report From Private Hospital Based Blood Centre In India.	Bala Bhasker	Received

PO-029	Association of red blood cell distribution width and lactate dehydrogenase with disease transformation in essential thrombocythaemia and polycythaemia vera patients: a UK cohort study using electronic health records	Lewis Carpenter	Received

EP-030	massive transfusion or massive confusion?	Mariem Cheikhrouhou	Received

PO-031	Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib	Ruben Mesa	Received

EP-031	Consequences of immune defects in patients with diffuse large B cell lymphoma (DLBCL).	Katarina Flatman	Received

PO-032	Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Nave Myelofibrosis Patients	Ruben Mesa	Received

EP-032	Relapsed/Refractory Hodgkins lymphoma: a real world analysis of salvage therapy in the East of England	Patrick Sarkies	Received

EP-033	Venous thromboembolism in newly diagnosed lymphoma patients: A review of 102 patients in a district general hospital aiming to identify those at risk	Aoife Dervin	Received

PO-033	Effects of cessation of venesection on serum ferritin level and liver function among older patients with haemochromatosis as a result of the Covid-19 pandemic.	Omolade Dada	Received

PO-034	Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic Jaki Nave Myelofibrosis Patients Independent of Baseline Platelet or Transfusion Status	Jean-Jacques Kiladjian	Received

EP-034	Osteoporotic fracture risk in Non-Hodgkins lymphoma patients over the age of 70 treated with glucocorticoid containing chemo-immunotherapy regimens; A retrospective audit at a District General Hospital	Patrick Isola	Received

PO-035	Characterisation of Cardiovascular Risk in a Contemporary Cohort of Patients with Myeloproliferative Neoplasms	Dipal Mehta	Received

EP-035	Experience of delivering MATRIX chemotherapy and autologous stem cell transplant for central nervous system lymphoma within South East Scotland	Sarah Beverstock	Received

PO-036	Pegylated Interferon is an effective and well-tolerated cytroreductive agent in patients with myeloproliferative neoplasms aged over 60 years.	Hannah Al-Yousuf	Received

EP-036	Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial	Lay Ean Tan	Received

PO-037	Iron Status of Pregnant Women with Sickle Cell Disease (SCD)	Edeghonghon Olayemi	Received

EP-037	Course features and the effect of various therapies on the treatment outcome of hepatitis C associated marginal zone lymphoma (HCVMLZ)	Sergey Lepkov	Received

PO-038	Enhancing chronic myeloid leukaemia (CML) patient safety and treatment management - Development of a management and audit tool for patients on tyrosine kinase inhibitor (TKI) therapy.	Toby Jones	Received

EP-038	Ibrutinib therapy related uveitis: A single-centre case series and literature review	Anita J M Kalakonda	Received

EP-039	Management of Primary Testicular Lymphoma within South-East Scotland within the last 10 years	Jennifer Clarke	Received

PO-039	Assessing the utility of peripheral blood monocyte analysis and the fraction of classical monocytes (CD14ve CD16-ve) in the diagnosis of Chronic Myelomonocytic Leukaemia.	Jennifer Mills	Received

EP-040	A Retrospective Analysis of the Covid-19 Pandemic Effect on Lymphoma Presentations and Diagnostic Pathways at Salisbury NHS Foundation Trust	Lee Grimes	Received

PO-040	Sickle screening of Blood Donors in Scotland using High Performance Liquid Chromatography. Are we opening Pandoras box?	Nicole Priddee	Received

EP-041	Quality of Life Reported Outcomes in Published Research on Waldenstroms Macroglobulinaemia: A systematic literature review	Sotirios Bristogiannis	Received

PO-042	An audit of compliance with BSH haemoglobinopathy patients transfusion requirements and antibody prevalence in UK tertiary centre hospital blood bank.	Suzanne Makki	Received

EP-043	Impact of CD38 Gene Polymorphism (rs1800561) on Hematological Parameters and Clinical Staging in Patients with Chronic Lymphocytic Leukemia	Sahar Elbager	Received

PO-043	Time to first plasma exchange in TTP - a regional Scottish experience	Christopher Mullen	Received

EP-044	Results of the treatment of patients with local stages of Hodgkins lymphoma	Evgeniya Paramonova	Received

PO-045	Assessment of intoxication indexes in local cold injury	Gennadiy Kovalov	Received

PO-046	Improving compliance with blood and platelet transfusion thresholds on a tertiary haematology ward	Jenny Jia Ling Cao	Received

EP-046	Outcomes of patients referred with lymphadenopathy to the haematology service in the London North West University Healthcare NHS Trust between January 2019 and March 2021	Clemency Britton	Received

EP-047	Comparing the Psychosocial Impacts of the COVID-19 Pandemic Between Haematological Cancer and Myeloma Patients: Findings From an Online Survey	Stephen Quinn	Received

PO-047	HIV, Hepatitis B and C viruses and syphilis coinfection among blood donors inhospital settings.	Supriya Kumari	Received

PO-048	Haematological changes & in-hospital mortality in severe COVID-19	Sergio Gama	Received

EP-048	Quality of life assessment in multiple myeloma is feasible, biologically meaningful and can suggest appropriate interventions.	Luke Carter-Brzezinski	Received

PO-049	ABO-related D-dimer elevation and severity In SARS-cov2-infected Tunisian patients	Amira Hourani	Received

EP-049	Real-world experience of thrombotic complications associated with immunomodulatory (IMID) therapy in newly diagnosed and relapsed patients with multiple myeloma (MM).	Lowri Morgan	Received

EP-050	Carfilzomib-related thrombotic microangiopathy a single centre case series	Muhammed Saleh	Received

PO-050	RDW: useful prognostic marker in acute COVID-19 infection	Sergio Gama	Received

EP-051	Survival in multiple myeloma patients following autologous stem cell transplantation, a single centre retrospective case series between 2015 and 2020	Rufaida Osman	Received

EP-052	Clinical utility of investigating for immune deficiency disease and light chain myeloma at low globulin levels	indra ramasamy	Received

EP-053	Pegcetacoplan Patient Compliance Rates In PEGASUS And PRINCE Phase 3 Trials Compared To Published Oral Medication Compliance Rates In Literature	Michael Yeh	Received

PO-053	Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results	Carmen Ramirez	Received

EP-054	The uptake of vaccinations in adults with sickle cell disease receiving care at the Cambridge University Hospitals NHS Foundation Trust	Joanna Kucharczak	Received

EP-055	Right dose, right time and right communication: patient feedback on management of acute painful episodes of sickle cell disease	Sophie Holmes	Received

PO-055	Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study	Sukanya Chaudhury	Received

PO-056	Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study	Sukanya Chaudhury	Received

EP-056	Thromboprophylaxis for Nursing home residents with COVID-19 a single centre approach	Radha Shah	Received

PO-057	Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma	Jacqueline Webster	Received

EP-057	Pattern of Venous Thrombosis events in 2020 associated with COVID, in a large teaching hospital	Huw Rowswell	Received

PO-058	Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study	Will Cherry	Received

EP-058	ASSOCIATION OF MEAN PLATELET VOLUME / PLATELET COUNT RATIO WITH CLINICAL SEVERITY AND INFARCT VOLUME IN PATIENTS WITH ACUTE ISHEMIC STROKE	Muhammad Wasi Nayyar	Received

PO-059	Real-World Experience of Rapid Obinutuzumab Administration: Time to Change Obinutuzumab Infusion Rates	Joel Cunningham	Received

EP-059	A single centre retrospective review looking at antiphospholipid screens for those on DOACs including follow up testing and the subsequent clinical sequelae.	Michelle Melly	Received

EP-060	Increased levels of factor VIII on admission, predict intensive care unit transferal and mortality in hospitalized COVID-19 patients.	Mohamed El Horri	Received

PO-060	Outcomes and prognostic factors for adult patients with Post-Transplant Lymphoproliferative Disorders: the Thames Valley experience	Maria Chiara Barbanti	Received

PO-061	The MCL Biobank Observational Study comes of age	Sarah Mant	Received

EP-061	Collaborative anticoagulation counselling for recently discharged patients: From hospital to the community pharmacy	Abigail Mezzullo	Received

EP-062	Subcutaneous unfractionated heparin in patients with end stage kidney disease requiring anticoagulation	Giulia Simini	Received

PO-062	BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)	Sukanya Chaudhury	Received

PO-063	Bisphosphonate prophylaxis in Lymphoma patients treated with steroid containing regimens	Rashmi Chandrashekar	Received

EP-063	Improving venous thromboembolism risk assessment practice and prophylaxis prescription for the patients admitted to medical assessment unit	Amar Ali	Received

EP-064	Case series of the first use of Andexanet Alfa at Salisbury NHS Foundation Trust	Lee Grimes	Received

PO-064	Efficacy of Mogamulizumab in Mycosis Fungoides by Patient Blood Involvement and Time to Response Analysis in Mycosis Fungoides and Sézary Syndrome: a Post Hoc Analysis of the MAVORIC Study	Lay Ean Tan	Received

EP-065	A retrospective review of the role of platelet aggregometry in the diagnosis of platelet disorders in a single Comprehensive care centre	Benjamin Gray	Received

PO-065	Undiagnosed Lymphadenopathy Pathway Is a Haematology-led service warranted?	Rachel Wright	Received

PO-066	Clinical Outcomes in Relapsed DLBCL Patients Approved for CAR-T Therapy; a Single Centre Study	John Hall	Received

PO-067	Real-World Outcomes for Dexamethasone, Rituximab and Cyclophosphamide (DRC) in the Treatment of Waldenström Macroglobulinaemia: An Eight-Year Retrospective Review	Ravindu De Silva	Received

EP-067	An audit of therapeutic anticoagulation with Anti-Xa monitoring during pregnancy	Sajida Kazi	Received

PO-068	Identification of a Novel Proliferating Cell Fraction in Chronic Lymphocytic Leukaemia with High Expression of IgM and Chemokine Receptors	Robbert Hoogeboom	Received

EP-068	ALLELE Study: A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV PTLD) after Failure of Rituximab	Sridhar Chaganti	Received

PO-069	A novel cardio-oncology pathway for the detection of early toxicity in patients receiving anthracycline chemotherapy for lymphoma	Clare Bannister	Received

EP-070	Is Posaconazole Therapeutic Drug Monitoring Required In Primary Prophylaxis Of Invasive Fungal Disease In Adult Allogeneic Stem Cell Recipients?	David Quinn	Received

PO-070	BRUIN MCL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Nave Mantle Cell Lymphoma (Trial in Progress)	Sukanya Chaudhury	Received

PO-071	CARTITUDE-2 Cohort B: Efficacy and Safety of Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T-Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients With Multiple Myeloma and Early Relapse After Initial Treatment	Priyanka Nair	Received

EP-071	Reduced intensity conditioning with fludarabine,treosulfan and anti-thymocyte globulin (FluTreoATG) - A single centre experience	Yadanar Lwin	Received

EP-072	Pregnancy outcomes following bone marrow transplant: findings of clinician survey and update on data linkage and UKOSS survey	Katherine Birchenall	Received

PO-072	First Results From CC-92480-MM-002: A Phase 1/2 Study Of The Potent, Novel CELMoD Agent CC-92480, In Combination With Dexamethasone And Bortezomib In Patients With Relapsed/Refractory Multiple Myeloma	Jared Saunders	Received

EP-073	A real-world evidence systematic literature review of the metrics used to detect veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation	Diane Lockard	Received

EP-074	The emerging advanced nurse practitioner role in haematology-does it cause confusion or provide support to the traditional clinical nurse specialist role?	Roxanne Spencer	Received

EP-075	Nurse-led Telephone Clinics for Myeloproliferative Neoplasms (MPN): Developing service provision through COVID-19	Hayley Gleadhill	Received

PO-075	Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multipl	Salgo Elenjikamalil	Received

EP-076	Role of IL6 in developing resistance of AML cells to standard chemotherapy	Ahmed Elmarghany	Received

PO-076	The impact of a delayed diagnosis on myeloma patients quality of life	Amy Capper	Received

PO-077	Treatment delivery and outcomes in elderly myeloma patients at The Royal Bournemouth hospital; Real life data	Alistair Smith	Received

EP-077	Pattern of Haemolysis During Pregnancy in Women with Sickle Cell Disease (SCD), and its Effects on Feto-maternal Outcome	Edeghonghon Olayemi	Received

EP-078	Real World Data on Efficacy of Pharmaceutical-grade L-glutamine in preventing Sickle Cell Disease-related acute complications and haemolysis in Pediatric and Adult patients.	Mohamed Yassin	Received

PO-079	Haematology clinic presentation of benign plasma cell granuloma and lymphomatoid granulomatosis with intracranial involvement - a case series.	Kanchana De Abrew	Received

EP-079	An Audit Of The Process Of Care In Surveillance Services For Children With Sickle Cell Disease In Wales	Charlie Jeffkins	Received

EP-080	Prevalence of Bleeding Disorders in Nicaragua in the period 2004-2020.	Sergio Luis Gustavo Aguilera Covarrubias	Received

EP-081	Beginning of the Hemophilic Arthropathy in children of 7 to 11 years old in Nicaragua in the absence of replacement treatment: Series of 9 cases.	Sergio Luis Gustavo Aguilera Covarrubias	Received

PO-081	Outcomes of Patients (pts) with Previously Treated Multiple Myeloma (MM) from European Countries and the United Kingdom, Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) Versus Bortezomib and Dexamethasone (Vd): A Post-Hoc Analysis from the BOS	Tamar Aprahamian	Received

PO-082	A META-ANALYSIS OF THE RATE OF MALIGNANT PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: PRELIMINARY FINDINGS FROM A SYSTEMATIC REVIEW	Stephen Quinn	Received

PO-083	Are we looking for Monoclonal Gammopathy of Renal Significance (MGRS)? An audit of investigations in current clinical practice	Lisa Jeffers	Received

PO-084	Quality of Life and Symptom Burden of Paroxysmal Nocturnal HaemogIobinuria Among Patients Receiving C5 Inhibitors in the United States and Europe	Shaneil Sonecha	Received

PO-085	Retrospective analysis of the burden of vasoocclusive events experienced by sickle cell disease (SCD) patients in the integrated health and social care system in North West London	Amir Nawaz	Received

PO-086	The Pharmacokinetics, Pharmacodynamics, And Safety Of Intravenous Pegcetacoplan Administration In Healthy Subjects	Michael Yeh	Received

PO-087	Association of CR1 and C3 polymorphisms with C3-mediated extravascular haemolysis in Paroxysmal Nocturnal Haemoglobinuria	April Joy Baral	Received

PO-089	Real-World Experience of Patients With Sickle Cell Disease Treated With Voxelotor: A Multicenter, Retrospective Study	Biree Andemariam	Received

PO-090	Pegcetacoplan Treatment In Patients With Paroxysmal Nocturnal Hemoglobinuria And Baseline Hemoglobin Levels At Or Above 10 g/dL	Michael Yeh	Received

PO-091	Predictors for improvement in patient-reported outcomes: post-hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-nave patients with paroxysmal nocturnal hemoglobinuria (PNH)	Colin Griffin	Received

PO-094	Breakthrough Hemolysis Rates Among Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switched From Eculizumab to Ravulizumab Treatment: A Real-World Analysis	Michael Yeh	Received

PO-095	Management of autoimmune haemolytic anaemia during pregnancy or post-partum: a single centre experience.	Marta Bortolotti	Received

PO-096	Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation From International PNH Registry Patient Data	Colin Griffin	Received

PO-098	Mapping the Prothrombin Binding Site of Pseutarin C by Site-directed PEGylation	Fatma Isik Ustok	Received

PO-099	Efficacy of thrombopoietin receptor agonists in Evans syndrome: an international multicenter experience	Nicola Cecchi	Received

PO-101	Postdischarge complications and mortality of hospitalised patients with COVID-19 in East London Hospitals	Aiman Entwistle	Received

PO-102	Drug-induced thrombotic thrombocytopenic purpura (TTP): review of European and North American pharmacovigilance report data	Sara Hosseinzadeh	Received

PO-103	Safety and Efficacy of Apixaban as Thromboprophylaxis in Multiple Myeloma Patients Receiving Chemotherapy: a Prospective Cohort Study	Zara Sayar	Received

PO-105	Platelet function abnormalities are common amongst women with menorrhagia referred for surgical intervention	Alison Delaney	Received

PO-107	The advantages of using expansion microscopy to visualise single platelets and aggregates	Raluca Alexandra Iulia Neagoe	Received

PO-108	Tranexamic Acid use to improve outcomes in Meningioma Surgery	Abigail Clynch	Received

PO-109	Internal and external validation of venous thromboembolism predictive model in hematologic malignancies.	Agnerys López Sacerio	Received

PO-110	Thromboembolism in COVID-19 patients on ECMO	Can Jones	Received

PO-111	Vaccine Induced Immune Thrombocytopenia and Thrombosis Syndrome post second dose of ChAdOx1 nCov-19 vaccine: Case Presentation	Amy Webster	Received

PO-113	The effect of lockdown and media coverage following vaccine rollout on Deep Vein Thrombosis (DVT) clinic activity during the first year of the COVID-19 pandemic a single-centre experience.	George Bell	Received

PO-114	Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma	Patrick Deifik	Received

PO-115	Excellent outcome with FB4 conditioning regimen in patients affected with myeloid malignancies older than 55 and with HCTI-score 2. A new insight for raising the upper limit for myeloablation in fit patients and high-risk diseases.	Daniele Avenoso	Received

PO-116	Use of a foamy-virus vector system to produce an off-the-shelf anti-CD19 CAR T cell product	Ioanna Lazana	Received

PO-118	The future of Outpatient Haematology : Self Supported Follow-up (SSFU) for patients with Chronic Lymphocytic Leukaemia (CLL) and Monoclonal Gammopathy of Undetermined Significance (MGUS) - An online Portal audit.	Ruth Jackson	Received

PO-121	Just one thing what would myeloma patients change about their treatment and care?	Jess Turner	Received

PO-122	Disease Knowledge in Adolescents and Young Adults with Sickle Cell Disease in a Low Resource Setting.	Bonaventure Ikediashi	Received

PO-123	What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?	Nick Fordham	Received

PO-124	Aberrant expression of lncRNA leukemia-induced non-coding activator RNA predicts poor Outcome in Childhood T-Acute Lymphoblastic Leukemia	Nashwa El-Khazragy	Received

PO-125	National protocol required for consistent transfusion duration in patients having regular tranfusion ? Resulrs from a national survey and recommendations	Eleni Louka	Received

PO-126	Need to contextualize the fight against sickle cell disease in regions with limited resources: the case of the Democratic Republic of the Congo	Abdala Aimé	Received

PO-127	APPRAISAL OF QUALITY OF LIFE AND ASSESMENT OF FACTORS INFLENCING QUALITY OF LIFE IN TRANSFUSION DEPENDENT BETA THALESEMMIA - A CROSS SECTIONAL STUDY	Srividhya Senthil	Received

PO-128	Individualized prophylaxis with personalized target trough FVIII level optimized clinical outcomes in boys with severe hemophilia A	Kun Huang	Received

PO-129	Thrombopoietin receptor agonists for treatment of new and relapsed immune thrombocytopenia in children- a single centre experience	Eman Hassan	Received

PO-130	DVT prophylaxis in sixteen and seventeen-year-olds and the NICE guidelines should adult risk assessment tools be used for children?	Jan Muhammad	Received

PO-131	A year of coagulation studies in a Paediatric Emergency Department: A service evaluation project	John Wilson	Received

PO-132	Positive Impact of Covid-19 on Providing Health Care Services: Experience from a Large Haemophilia Comprehensive Care Centre	Emma Whiting	Received

PO-133	Single Centre Study on Safety and Efficacy of Rivaroxaban in Paediatric Venous Thromboembolism	Eman Hassan	Received

PO-134	Impact of levofloxacin-based prophylaxis during the pre-engraftment phase in allogeneic hematopoietic stem cell transplant pediatric recipients: a single-center retrospective matched analysis.	Martina DAgostin	Received

62nd Annual Scientific Meeting of the British Society for Haematology

3-5 April 2022 Manchester

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 03/04/2022 TO 03/04/2023

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access